A Novel Aldisine Derivative Exhibits Potential Antitumor Effects by Targeting JAK/STAT3 Signaling

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Oncology

Background:

• The Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway is frequently hyperactivated in various cancers.
• This aberrant activation promotes tumor cell proliferation, survival, invasion, and metastasis, making it a critical therapeutic target.
• Targeting JAK/STAT3 offers significant potential for developing novel anticancer treatments.

Purpose of the Study:

• To design, synthesize, and evaluate novel aldisine derivatives as potential inhibitors of the JAK/STAT3 signaling pathway.
• To identify specific compounds with improved antitumor activity by introducing an isothiouronium group.
• To assess the efficacy of these compounds in preclinical cancer models.

Main Methods:

• High-throughput screening of 3157 compounds to identify JAK/STAT3 inhibitors.
• Synthesis of modified aldisine derivatives incorporating isothiouronium groups.
• In vitro assays to evaluate antiproliferative activity, pan-JAK inhibition, and STAT3 activation inhibition.
• Analysis of STAT3 downstream gene expression (Bcl-xl, C-Myc, Cyclin D1) and induction of apoptosis.
• In vivo studies using a subcutaneous tumor xenograft model.

Main Results:

• Compounds 11a, 11b, and 11c, featuring a pyrrole [2,3-c] azepine core linked to an isothiouronium group, significantly inhibited JAK/STAT3 activity.
• Compound 11c demonstrated optimal antiproliferative effects and acted as a pan-JAKs inhibitor, blocking both constitutive and IL-6-induced STAT3 activation.
• Compound 11c dose-dependently induced apoptosis in A549 and DU145 cancer cells and modulated key downstream genes.
• In vivo experiments confirmed the antitumor efficacy of compound 11c in a DU145 xenograft model.

Conclusions:

• A novel series of small molecule JAKs inhibitors targeting the JAK/STAT3 pathway were successfully designed and synthesized.
• Compound 11c exhibits significant preclinical anticancer activity through inhibition of JAK/STAT3 signaling and induction of apoptosis.
• These findings suggest that compound 11c holds therapeutic promise for treating cancers characterized by JAK/STAT3 pathway overactivation.